State CT
Clinical Trials in Connecticut
Recruiting clinical trials with at least one study location in Connecticut. Data updated daily from ClinicalTrials.gov.
Top Conditions in Connecticut
Frequently Asked Questions — Clinical Trials in Connecticut
How many clinical trials are currently recruiting in Connecticut?
ClinicalMetric currently tracks 201 actively recruiting clinical trials with at least one location in Connecticut. The total number of registered studies—including active but not currently enrolling trials—is 201. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Connecticut?
Connecticut hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Alcohol Use Disorder, Advanced Solid Tumors, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Connecticut serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Connecticut?
To join a clinical trial in Connecticut, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Connecticut maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Connecticut
NCT01193075 N/A
Recruiting
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT...
Condition
Charcot Marie Tooth Disease
Enrollment
5,000 pts
Location
United States, Australia, Canada
Sponsor
Michael Shy
NCT06581432 Phase 2
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanc...
Condition
Solid Tumours
Enrollment
430 pts
Location
United States, Australia, Belgium
Sponsor
Boehringer Ingelheim
NCT06496620 Phase 2
Recruiting
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Condition
COPD
Enrollment
171 pts
Location
United States, Australia, Canada
Sponsor
Uniquity One (UNI)
NCT06544499 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participan...
Condition
Primary Immune Thrombocytopenia (ITP)
Enrollment
69 pts
Location
United States, Austria, Bulgaria
Sponsor
argenx
NCT04130516 Phase 1, Phase 2
Recruiting
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801a...
Condition
Solid Tumor, Adult
Enrollment
200 pts
Location
United States
Sponsor
Linnaeus Therapeutics, Inc.
NCT07415044 Phase 2
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Condition
Ulcerative Colitis (UC)
Enrollment
1,431 pts
Location
United States, Argentina, Brazil
Sponsor
Eli Lilly and Company
NCT06315738 Phase 1, Phase 2
Recruiting
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in I...
Condition
Necrotizing Enterocolitis
Enrollment
36 pts
Location
United States
Sponsor
Noveome Biotherapeutics, forme
NCT06500884 Phase 2
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Condition
Multiple Myeloma
Enrollment
210 pts
Location
United States, Brazil, Netherlands
Sponsor
Janssen Research & Development
NCT04176198 Phase 1, Phase 2
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Condition
Myelofibrosis
Enrollment
240 pts
Location
United States, Australia, Belgium
Sponsor
Sumitomo Pharma America, Inc.
NCT06297993 N/A
Recruiting
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosi...
Condition
PSC
Enrollment
2,000 pts
Location
United States, Canada, Germany
Sponsor
PSC Partners Seeking a Cure
NCT05746533 N/A
Recruiting
An Evaluation of Hip Preservation Outcomes
Condition
Hip Arthroscopy
Enrollment
10,000 pts
Location
United States
Sponsor
Yale University
NCT05260047 N/A
Recruiting
Culturally Responsive Community Driven Substance Use Recovery for Black and Lati...
Condition
Substance Use
Enrollment
525 pts
Location
United States
Sponsor
Yale University
NCT06636383 N/A
Recruiting
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Condition
Glycogen Storage Disease Type Ia
Enrollment
140 pts
Location
United States, Brazil, Canada
Sponsor
Ultragenyx Pharmaceutical Inc
NCT06513819 Phase 1
Recruiting
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP...
Condition
Hiv
Enrollment
100 pts
Location
United States
Sponsor
Yale University
NCT03556228 Phase 1, Phase 2
Recruiting
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpr...
Condition
Head and Neck Carcinoma
Enrollment
242 pts
Location
United States, Puerto Rico
Sponsor
VM Oncology, LLC
NCT07375537 N/A
Recruiting
FLIGHT - Autism: Education and Health Coaching Program Focused on Modifiable Lif...
Condition
Autism
Enrollment
12 pts
Location
United States
Sponsor
Documenting Hope Project
NCT04333537 Phase 2, Phase 3
Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Pat...
Condition
Buccal Mucosa Squamous Cell Carcinoma
Enrollment
686 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT05684965 Phase 1, Phase 2
Recruiting
XTX301 in Patients With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
358 pts
Location
United States
Sponsor
Xilio Development, Inc.
NCT07252232 Phase 3
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Ade...
Condition
Pancreatic Cancer
Enrollment
500 pts
Location
United States, Puerto Rico, United Kingdom
Sponsor
Revolution Medicines, Inc.
NCT06142955 N/A
Recruiting
Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum D...
Condition
Autism Spectrum Disorder
Enrollment
60 pts
Location
United States
Sponsor
Yale University
NCT05243797 Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Al...
Condition
Multiple Myeloma
Enrollment
1,594 pts
Location
United States, Argentina, Australia
Sponsor
European Myeloma Network B.V.
NCT07285213 Phase 2
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Ant...
Condition
Clostridioides Difficile Infection
Enrollment
230 pts
Location
United States, Australia, Canada
Sponsor
AstraZeneca
NCT06632457 Phase 3
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a L...
Condition
Metabolic Dysfunction Associated Steatohepatitis
Enrollment
1,590 pts
Location
United States, Argentina, Australia
Sponsor
Boehringer Ingelheim
NCT06058377 Phase 3
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy T...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
3,680 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT07042100 Phase 1
Recruiting
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced...
Condition
Advanced Solid Tumors
Enrollment
177 pts
Location
United States, Australia, India
Sponsor
Sun Pharma Advanced Research C
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology